Roche Reports Results of Tecentriq in P-III IMpower010 Study for Patients with Early Lung Cancer

March 23, 2021 Auto Bot Clinical Trials, Non-Small Cell Lung Cancer, Roche, Tecentriq 0

Shots:

  • The P-III IMpower010 study involves assessing Tecentriq vs BSC, in 1,005 participants in a ratio (1:1) with stage IB-IIIA NSCLC, following surgical resection and up to 4 cycles of adjuvant CT
  • The study met its 1EPs showed improvement in DFS in PD-L1+ stage II-IIIA populations and ITT stage IB-IIIA populations NSCLC. The 2EP’s include OS in the overall study population, ITT Stage IB-IIIA NSCLC
  • The findings will be submitted to US FDA and EUA and presented at an upcoming medical meeting. Tecentriq is approved in the US, EU, and other countries, either alone or in combination with targeted therapies and/or CT in multiple cancer indications

Click here ­to­ read full press release/ article | Ref: Roche | Image: CTV News

The post Roche Reports Results of Tecentriq in P-III IMpower010 Study for Patients with Early Lung Cancer first appeared on PharmaShots.